Jacobus Pharmaceutical Co. Inc. won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

A 2017 study found that more than 700 million adults and children worldwide are obese, calling it a “rising pandemic.”

Gotham Therapeutics launched in New York with a $54 million Series A financing. The round was co-led by founding investor Versant Ventures, Forbion, and S.R. One.